Adenosquamous cell lung cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:12:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adenosquamous cell lung cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of JK06 for Patients with Advanced or Metastatic Cancer https://clinicaltrials.eu/trial/study-of-jk06-for-patients-with-advanced-or-metastatic-cancer/ Wed, 29 Apr 2026 15:01:44 +0000 https://clinicaltrials.eu/trial/study-of-jk06-for-patients-with-advanced-or-metastatic-cancer/ This clinical trial is focused on studying a new treatment for patients with unresectable locally advanced or metastatic cancer. The treatment being tested is called JK06, which is a type of medication known as an antibody-drug conjugate (ADC). This medication is given to patients through an infusion into a vein, which means it is delivered directly into the bloodstream. The study aims to understand how safe and tolerable this treatment is for patients, as well as to determine the best dose to use in future studies.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

]]> Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC). The study is exploring a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy is designed to target specific mutations found in cancer cells. The study will also look at how ATL001 works when used alone and in combination with another medication called pembrolizumab, which is already used in cancer treatment.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

]]> Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings https://clinicaltrials.eu/trial/study-on-the-accuracy-of-owl-evo1-test-for-diagnosing-lung-cancer-in-patients-eligible-for-screening-or-with-suspicious-ct-findings/ Wed, 29 Apr 2026 14:26:14 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-owl-evo1-test-for-diagnosing-lung-cancer-in-patients-eligible-for-screening-or-with-suspicious-ct-findings/ This clinical trial is focused on studying lung cancer and involves a new test called the OWL-EVO1 Breath Biopsy test. The test aims to help differentiate between individuals who may have lung cancer and those who do not. The study will use a special solution called D5-ethyl-beta-D-glucuronide, which is given through an infusion into the veins. This solution is a water-soluble substance that helps in the testing process.

The purpose of the study is to assess how accurately the OWL-EVO1 test can identify lung cancer in people who are undergoing screening or have findings on a CT scan that might suggest lung cancer. Participants will receive the test and be monitored to see how well it works in identifying lung cancer compared to other conditions that might look similar on a scan. The study will also look at the safety and tolerability of the test, ensuring that it is safe for participants to use.

Throughout the study, participants will receive the test and be observed over a period of time to gather information on its effectiveness and safety. The study will help determine if the OWL-EVO1 test can be a reliable tool for diagnosing lung cancer, potentially leading to earlier and more accurate detection of the disease.

]]>